Bralin

acute period of ischemic stroke (as part of complex therapy),

recovery period of ischemic and hemorrhagic strokes,

TBI, acute (as part of complex therapy) and recovery period,

cognitive and behavioral disorders in degenerative and vascular diseases of the brain.

acute period of ischemic stroke (as part of complex therapy),

recovery period of ischemic and hemorrhagic strokes,

traumatic brain injury, acute (as part of complex therapy) and recovery periods,

cognitive and behavioral disorders in degenerative and vascular diseases of the brain.

Solution for intravenous, intravenous administration.

I / V, in the form of a slow I / V injection (for 3-5 minutes, depending on the prescribed dose) or a drip I/V infusion (40-60 drops per minute).

The I/V route of administration is preferable to the I / m route. When administered intravenously, repeated administration of the drug in the same place should be avoided.

Recommended dosage regimen

Acute period of ischemic stroke and TBI: 1000 mg every 12 hours from the first day after diagnosis, the duration of treatment is not less than 6 weeks. After 3-5 days after the start of treatment (if the swallowing function is not impaired), it is possible to switch to oral forms of the drug Bralin^®.

Recovery period of ischemic and hemorrhagic strokes, recovery period of TBI, cognitive and behavioral disorders in degenerative and vascular diseases of the brain: 500-2000 mg per day. The dosage and duration of treatment — depending on the severity of the symptoms of the disease. It is possible to use oral forms of the drug Bralin^®.

Elderly patients

When prescribing the drug Bralin^® elderly patients do not need to adjust the dose.

The solution in the ampoule is intended for single use. It should be used immediately after opening the ampoule.

The drug is compatible with all types of intravenous isotonic solutions and dextrose solutions.

Solution for oral administration.

Before use, the drug can be diluted in a small amount of water (120 ml or 1/2 cup). Take it with a meal or between meals.

Recommended dosage regimen

Acute period of ischemic stroke and TBI: 1000 mg (10 ml or 1 pack)) every 12 hours. The duration of treatment is not less than 6 weeks.

Recovery period of ischemic and hemorrhagic strokes, recovery period of TBI, cognitive and behavioral disorders in degenerative and vascular diseases of the brain: 500-2000 mg per day (5-10 ml or 1 pack).(1000 mg) 1-2 times a day). The dosage and duration of treatment — depending on the severity of the symptoms of the disease.

Elderly patients

When prescribing the drug Bralin^® elderly patients do not need to adjust the dose.

Instructions for using the dosage syringe (fig. 1):

Figure 1.

1. Place the dosing syringe in the vial (the plunger of the syringe is completely lowered) (Fig. 1 (1).

2. Gently pull the plunger of the dosing syringe until the solution level is equal to the corresponding mark on the syringe (Fig. 1 (2).

3. Before taking the desired amount of solution can be diluted in 1/2 cup of water (120 ml) (Figure 1 (3).

After each use, it is recommended to rinse the dosage syringe with water.

Recommendations for the use of the drug Bralin^® in bags:

1. Separate one bag from the other along the tear-off seam. Holding the bag vertically, carefully tear off its edge at the mark "Open here" (Fig. 2).

Figure 2.

2. The contents of the bag can be drunk immediately after opening (Fig. 3) or before taking it can be diluted in 1/2 cup of water (120 ml) (Figure 4).

Figure 3.

Figure 4.

Inside, during meals or between meals. Before use, the drug can be diluted in a small amount of water (120 ml or 1/2 cup).

Doses are calculated based on the content of citicoline in 1 ml (100 mg), in 1 pack. (10 ml) contains 1000 mg of citicoline, in 1 fl. (30 ml) - 3000 mg.

Recommended dosage regimen

Acute period of ischemic stroke and TBI. 1000 mg (10 ml) every 12 hours. The duration of treatment is not less than 6 weeks.

Recovery period of ischemic and hemorrhagic strokes, TBI, cognitive and behavioral disorders in degenerative and vascular diseases of the brain. 500-2000 mg (5-20 ml) per day. The dosage and duration of treatment depend on the severity of the symptoms of the disease.

Special patient groups

Old age. When prescribing the drug Bralin^® elderly patients do not need to adjust the dose.

Instructions for use of the drug Bralin in vials using the pipette supplied with it dosing

1. Place the dosing pipette in the bottle (the pipette plunger is completely lowered).

2. Gently pull the plunger of the pipette dispenser until the solution level is equal to the corresponding mark on the pipette.

3. Before taking the desired amount of solution can be diluted in 1/2 cup of water (120 ml).

After each use, it is recommended to rinse the pipette with water.

Recommendations for the use of the drug Bralin^® in bags

1. Take a bag of Bralin^® grab the edge and shake.

2. Tear off the edge of the bag in the place indicated by the dotted line.

3. Drink the contents of the bag immediately after opening or dissolve in 1/2 cup of drinking water (120 ml) and drink.

hypersensitivity to any of the components of the drug,

pronounced vagotonia (predominance of the tone of the parasympathetic part of the autonomic nervous system),

rare hereditary diseases associated with fructose intolerance,

children under 18 years of age (due to the lack of sufficient clinical data).

hypersensitivity to any of the components of the drug,

pronounced vagotonia (predominance of the tone of the parasympathetic part of the autonomic nervous system),

rare hereditary diseases associated with fructose intolerance,

children under 18 years of age (due to the lack of sufficient clinical data).

Frequency of side effects

Very rare (<1/10000) (including individual cases): allergic reactions (rash, itching, anaphylactic shock), headache, dizziness, feeling hot, tremor, nausea, vomiting, diarrhea, hallucinations, edema, shortness of breath, insomnia, agitation, decreased appetite, numbness in paralyzed limbs, changes in the activity of liver enzymes. In some cases, Bralin^® it can stimulate the parasympathetic system, as well as cause a short-term change in blood pressure.

If any of the side effects listed in the instructions are aggravated, or any other side effects not listed in the instructions have been noticed, you should inform your doctor.

Very rare (<1/10000) - allergic reactions (rash, itching, anaphylactic shock), headache, dizziness, feeling hot, tremor, nausea, vomiting, diarrhea, hallucinations, edema, shortness of breath, insomnia, agitation, decreased appetite, numbness in paralyzed limbs, changes in the activity of liver enzymes. In some cases, the drug Bralin^® it can stimulate the parasympathetic system, as well as have a short-term effect on the blood pressure level.

If any of the side effects listed in the description worsen or any other side effects not listed in the description appear, you should inform your doctor.

Citicoline, being a precursor of key ultrastructural components of the cell membrane (mainly phospholipids), has a wide spectrum of action-it promotes the restoration of damaged cell membranes, inhibits the action of phospholipases, prevents the excessive formation of free radicals, and also prevents cell death by affecting the mechanisms of apoptosis. In the acute period of stroke, citicoline reduces the volume of brain tissue damage, improves cholinergic transmission. With TBI, it reduces the duration of post-traumatic coma and the severity of neurological symptoms, in addition, it helps to reduce the duration of the recovery period

In chronic brain hypoxia, citicoline is effective in the treatment of cognitive disorders, such as memory impairment, lack of initiative, difficulties in performing daily activities and self-care. Increases the level of attention and consciousness, and also reduces the manifestation of amnesia.

Citicoline is effective in the treatment of sensitive and motor neurological disorders of degenerative and vascular etiology.

Citicoline, as a precursor of key ultrastructural components of the cell membrane (mainly phospholipids), has a broad spectrum of activity — helps to restore damaged cell membranes, inhibits the action of phospholipase, prevents the excessive formation of free radicals and prevent cell death by acting on the mechanisms of apoptosis. In the acute period of stroke, it reduces the volume of brain tissue damage, improves cholinergic transmission. With TBI, it reduces the duration of post-traumatic coma and the severity of neurological symptoms, in addition, it helps to reduce the duration of the recovery period

Citicoline is effective in the treatment of cognitive, sensory and motor neurological disorders of degenerative and vascular etiology.

In chronic cerebral ischemia, citicoline is effective in the treatment of disorders such as memory impairment, lack of initiative, and difficulties in performing daily activities in self-care. Increases the level of attention and consciousness, as well as reduces the manifestations of amnesia.

Suction. Citicoline is well absorbed by intravenous and intravenous administration. Absorption after oral administration is almost complete, and bioavailability is almost the same as after intravenous administration.

Metabolism. With intravenous and intravenous administration, citicoline is metabolized in the liver to form choline and cytidine. After administration, the concentration of choline in the blood plasma increases significantly.

Distribution. Citicoline is largely distributed in the structures of the brain, with the rapid introduction of choline fractions into structural phospholipids and cytidine fractions into cytidine nucleotides and nucleic acids. Citicoline penetrates into the brain and is actively embedded in cellular, cytoplasmic and mitochondrial membranes, forming part of the structural phospholipid fraction.

Output. Only 15% of the administered dose of citicoline is excreted from the human body, less than 3% - by the kidneys and about 12% - with exhaled CO₂.

In the excretion of citicoline in the urine, 2 phases can be distinguished: the first phase, lasting about 36 hours, during which the rate of excretion decreases rapidly, and the second phase, during which the rate of excretion decreases much more slowly. The same is observed in the exhaled CO₂ - the elimination rate decreases rapidly after about 15 hours, and then decreases much more slowly.

Suction. Citicoline is well absorbed when taken orally. Absorption after oral administration is almost complete, and bioavailability is approximately the same as after intravenous administration.

Metabolism. The drug is metabolized in the intestine and liver to form choline and cytidine. After administration, the concentration of choline in the blood plasma increases significantly.

Distribution. Citicoline is largely distributed in the structures of the brain, with the rapid introduction of choline fractions into structural phospholipids and cytidine fractions into cytidine nucleotides and nucleic acids. Citicoline penetrates into the brain and is actively embedded in cellular, cytoplasmic and mitochondrial membranes, forming part of the structural phospholipid fraction.

Output. Only 15% of the administered dose of citicoline is excreted from the human body: less than 3% - by the kidneys and through the intestines, and about 12% - with exhaled air.

In the excretion of citicoline in the urine, 2 phases can be distinguished: Phase 1, lasting about 36 hours, during which the rate of excretion decreases rapidly, and phase 2, during which the rate of excretion decreases much more slowly. The same thing is observed in the exhaled air — the rate of excretion decreases rapidly after about 15 hours, and then decreases much more slowly.

• Nootropic agent [Nootropics]

• Nootropic agent [Other neurotropic agents]